Tag: tyrosine kinase inhibitor

In a phase 2a research using Lenvima and fostrox to treat hepatocellular cancer, Medivir has started treating patients.

The first patient with hepatocellular carcinoma (HCC) has begun treatment in phase 2a with the candidate drug fostroxacitabine bralpamide (fostrox) in combination with Lenvima, according to Medivir AB, a pharmaceutical company dedicated to creating novel cancer treatments in regions with…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram